Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 288 participants.

Also called NCT06880770

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 288 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06880770
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Austria, Belgium, Brazil, Bulgaria, Canada, China, Colombia, Croatia, Czechia, Georgia, Hungary, Israel, Jordan, Latvia, Lithuania, Mexico, Oman, Saudi Arabia, Serbia, Singapore, Slovakia, South Korea, Sweden, United Arab Emirates, United Kingdom (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06880770. Randomized; quadruple masking; primary purpose treatment. Start 2025-04-24 (actual); primary completion 2029-03 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis
Acronym
SHASTA-5
Condition
Severe Hypertriglyceridemia
Intervention (Drug)
Plozasiran
Intervention (Drug)
Placebo
Lead sponsor
Arrowhead Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct06880770
Content hash
47b56fd2858c0382865dd2260558a073d135cd46a4d2ae35e2540c7115071c13